HUBEI BIOCAUSE HEILEN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.49 CNY | -0.17% |
|
-6.27% | -19.59% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 515M 71.29M | Sales 2023 | 663M 91.8M | Capitalization | 6.26B 867M |
|---|---|---|---|---|---|
| Net income 2022 | 126M 17.44M | Net income 2023 | 176M 24.37M | EV / Sales 2022 | 12.4 x |
| Net cash position 2022 | 1.95B 271M | Net cash position 2023 | 1.82B 252M | EV / Sales 2023 | 6.71 x |
| P/E ratio 2022 |
66.6
x | P/E ratio 2023 |
35.7
x | Employees | 1,012 |
| Yield 2022 |
1.15% | Yield 2023 |
2.21% | Free-Float | 24.56% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.17% | ||
| 1 week | -6.27% | ||
| Current month | +0.29% | ||
| 1 month | +12.62% | ||
| 3 months | +5.30% | ||
| 6 months | -23.29% | ||
| Current year | -19.59% |
1 week
17.26
18.95
1 month
16.0019.39
Current year
14.0522.28
1 year
14.0531.56
3 years
13.2946.88
5 years
13.2946.88
10 years
13.2946.88
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Hao Yi
DFI | Director of Finance/CFO | 51 | 20-06-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ren Hui Fu
BRD | Director/Board Member | 44 | 23-04-19 |
Zhi Gang Cheng
CHM | Chairman | 50 | 20-06-25 |
Xue Qiang Huang
BRD | Director/Board Member | 57 | 20-06-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 17.49 | -0.17% | 2,172,592 |
| 24-05-16 | 17.52 | -1.18% | 2,787,490 |
| 24-05-15 | 17.73 | -1.88% | 2,693,115 |
| 24-05-14 | 18.07 | +0.39% | 4,428,964 |
| 24-05-13 | 18 | -0.72% | 6,592,200 |
End-of-day quote Shenzhen S.E., May 16, 2024
More quotes
Hubei Biocause Heilen Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and preparation products. The Company's products can be divided into non-steroidal anti-inflammatory, cardiovascular and anti-tumor. The API products include Ibuprofen, D-Ibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate and others. The preparation products include Ibuprofen Granules, Ibuprofen Tablets, Ibuprofen Pseudoephedrine Tablets, Oxaprozin Enteric Coated Tablets, Oxaprozin Enteric Coated Capsules, Torasemide Tablets and others. The Company's products are exported to India, the United States, the European Union, South Korea and other countries.
Sector
Pharmaceuticals
Calendar
2024-05-31
- Extraordinary Shareholders Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -19.59% | 699M | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 301211 Stock